Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence
2007

Impact of ADHD on Prescription Drug Spending for Children and Adolescents

publication Evidence: high

Author Information

Author(s): Michael Schlander

Primary Institution: Institute for Innovation & Valuation in Health Care (INNOVALHC)

Hypothesis

What are the future trends of ADHD-related drug expenditures for children and adolescents in Germany and England?

Conclusion

Providers of care for children and adolescents with ADHD should anticipate serious challenges related to the cost-effectiveness of interventions.

Supporting Evidence

  • ADHD pharmacotherapy expenditures for children and adolescents are projected to exceed €310 million in Germany by 2012.
  • Overall drug spending by individual physicians may increase 2.3- to 9.5-fold due to various factors.
  • Even in a low case scenario, a more than six-fold increase in pharmaceutical spending for ADHD is predicted over a decade.

Takeaway

The study predicts that spending on ADHD medications for kids will keep increasing a lot over the next few years, which could make it harder for doctors to manage costs.

Methodology

A model was developed to predict future pharmaceutical expenditures for ADHD based on demographic data, past spending trends, and new drug developments.

Potential Biases

There is uncertainty around future events, including the potential withdrawal of marketed drugs and the dynamic health policy environment.

Limitations

The analysis does not address the clinical appropriateness of prescriptions and is limited to pharmaceutical spending without considering other ADHD-related costs.

Participant Demographics

Children and adolescents aged 6 to 18 years with ADHD.

Digital Object Identifier (DOI)

10.1186/1753-2000-1-13

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication